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Abstract
Background: In 2002, Cameroon initiated scale up of antiretroviral therapy (ART); on 1 October 2004, a substantial
reduction in ART cost occurred. We assessed the impact of this event and other factors on enrolment and
retention in care among HIV-infected patients initiating ART from February 2002 to December 2005 at the single
ART clinic serving the Southwest Region in Limbe, Cameroon.
Methods: We retrospectively analyzed clinical and pharmacy payment records of HIV-infected patients initiating
ART according to national guidelines. We compared two cohorts of patients, enrolled before and after 1 October
2004, to determine if price reduction was associated with enhanced enrolment. We assessed factors associated
with retention and survival by Cox proportional hazards models. Retention in care implied patients who had
contact with the healthcare system as of 31 December 2005 (including those who were transferred to continue
care in other ART centres), although these patients may have interrupted therapy at some time. A patient who was
not retained in care may have dropped out (lost to follow up) or died.
Results: Mean enrolment rates for 2920 patients who initiated ART before and after the price reduction were
46.5 and 95.5 persons/month, respectively (p < 0.001). The probabilities of remaining alive and in care were 0.66
(95% CI 0.64-0.68) at six months, 0.58 (95% CI 0.56-0.60) at one year, 0.47 (95% CI 0.45-0.49) at two years and
0.35 (95% CI 0.32-0.38) at three years; they were not significantly different between the two cohorts of patients
enrolled before and after the price reduction over the first 15 months of comparable follow up (hazard ratio 1.1;
95% CI 0.9-1.2, p = 0.27). In multivariable analysis using multiple imputations to compensate for missing values,
factors associated with dropping out of care or dying were male gender (HR 1.33 [1.18-1.50], p = 0.003),
treatment paid by self, family or partly by other (HR 3.05 [1.99-4.67], p < 0.001), and, compared with residents of
Limbe, living more than 150 km from Limbe (HR 1.41 [1.18-1.69], p < 0.001), or being residents of Douala (HR
1.51 [1.16-1.98], p < 0.001).
Conclusions: Reducing the cost of ART increased enrolment of clients in the programme, but did not change
retention in care. In a system where most clients pay for ART, an accessible clinic location may be more important
than the cost of medication for retention in care. Decentralizing ART clinics might improve retention and survival
among patients on ART.
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Nearly two-thirds of the world’s estimated 33 million
HIV-infected adults live in sub-Saharan Africa [1]. In
response to this situation, the World Health Organiza-
tion (WHO), in collaboration with developing countries,
recommended the “3b y5 ” initiative: treatment of 3 mil-
lion people living with HIV/AIDS by the end of 2005 [2].
Treatment of HIV-infected patients with antiretroviral
therapy (ART) has been shown to suppress viral replica-
tion and dramatically extend survival [3-9]. Despite its
demonstrated benefits, access to ART remains limited in
resource-constrained settings. ART programmes in
developing countries face many challenges, including
large patient burdens, costly drugs, inadequate numbers
of trained healthcare staff, and laboratory facilities ill-
equipped to monitor patients receiving ART. For the
estimated 4 million HIV-infected patients who needed
therapy in sub-Saharan Africa in 2006, coverage was
16% [10]. In Cameroon, 46,000 (25%) of the estimated
180,000 HIV-infected patients eligible for ART were
receiving treatment in 2007 [11].
Since 2002, Cameroon has undertaken an initiative to
scale up access to ART. From 2002 until 2005, most
patients paid for ART themselves in Cameroon. On 1
October 2004, the cost to patients of ART was reduced
substantially. From 1999 to 2005, the average monthly
cost of first-line ART decreased by more than 100-fold,
while the per capita gross national income increased
from US$590 to US$630 [12] (World Bank 2004). Camer-
oon benefited from the Accelerating Access Initiative,
which reduced the initial price of antiretroviral drugs
from US$915 to US$128 per month in 2000. The initia-
tive was launched in May 2000 with six pharmaceutical
firms and five United Nations agencies (UNAIDS, the
World Bank, WHO, UNICEF and UNFPA).
Following negotiations with pharmaceutical firms and
subsidies from the government of Cameroon, the price
further decreased to between US$27.40 and US$51.20
per month in 2002. With Cameroon’s successful propo-
sal to the Global Fund to Fight AIDS, Tuberculosis and
Malaria (Global Fund), in which care for HIV-infected
patients was an integral component, on 1 October 2004
the price of antiretroviral drugs declined further to US
$5.50 and US$12.80 per month for first-and second-line
treatment regimens, respectively. Treatment units were
allowed to enrol up to 15% of all treated persons for
free ART. Global Fund-supported first-and second-line
ART regimens included nucleoside and non-nucleoside
reverse transcriptase inhibitor-based and protease inhibi-
tor-based ART.
Before 2005, the Limbe Regional Hospital ART clinic
was the sole clinic that provided ART in the Southwest
Region of Cameroon, a region that covers 25,410 km
2
with an estimated population of 1,100,000 inhabitants
[13]. As of December 2005, this ART clinic had enrolled
and initiated ART for more than 3000 HIV-infected
patients, representing about 17% of patients receiving
ART in Cameroon. In order to assess this programme’s
performance and to identify opportunities for improve-
ment, we analyzed factors associated with enrolment
and retention in care among HIV-infected patients initi-
ating ART between February 2002 and December 2005
at this clinic.
Methods
Antiretroviral therapy programme enrolment
HIV-infected patients were eligible for enrolment in the
Limbe ART programme if they met the following criteria
according to national guidelines: AIDS-defining illness or
symptomatic HIV disease or CD4 count of more than 200
cells/mm
3. The clinical staging used for entry into the
ART programme was changed from the US Centers for
Disease Control and Prevention (CDC) classification to
the WHO classification in 2005; therefore, persons were
eligible for ART if they had CDC stage A3, B2, B3 or C
disease, or WHO clinical stages 3 and 4 disease. ART was
dispensed monthly, although for patients for whom trans-
portation to the clinic was difficult, the clinic providers
could dispense two to three months of medication.
Procedures
We analyzed data that had been abstracted from
patients’ medical charts using standardized forms. These
data were entered and maintained in a single analysis
dataset (Microsoft Excel 2003, Microsoft Corp, Red-
m o n d ,W a s h i n g t o n ,U S A )a n di n c l u d e da g e ,s e x ,p a s t
medical history, prior treatment history (e.g., ART,
opportunistic infection prophylaxis, tuberculosis treat-
ment), functional status and WHO/CDC clinical stage,
presenting signs and symptoms, weight, entry and fol-
low-up CD4 cell counts, results of complete blood
counts (e.g., haemoglobin, white blood cell count), blood
chemistries (e.g., serum creatinine, liver transaminases),
and enrolment patterns (i.e., attendance).
To characterize access to the clinic, patients were cate-
gorized into those who: 1) were residents of Limbe; 2)
lived less than 40 km from Limbe; 3) lived 40-150 km
from Limbe; 4) lived more than 150 km from Limbe; and
5) were residents of Douala (74 km away on a main
road). Patient records did not provide information about
missed doses of medication. Adherence was measured by
the number of clinic visits attended, and defined as
“good” if a patient attended 95% or more of scheduled
clinic visits and “poor” if a patient attended between 80%
and 94% of scheduled visits; “non-adherent” was defined
as attending less than 80% of scheduled visits.
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the hospital premises, or if the death had been con-
firmed by hospital staff or a relative. Patients were clas-
sified as lost to follow up if they failed to return for
their last scheduled clinic visit and had not been seen
within 91 days prior to the end date of 31 December
2005. Patients who had contact with the healthcare sys-
tem, either during an initial visit or follow-up visit dur-
ing the 91 days prior to 31 December 2005, were
considered to be active and in care. We defined “active”
patients to be those who were still recorded in the pro-
gramme as of 31 December 2005, although the patient
may have interrupted therapy at some time.
Data analysis
We retrospectively analyzed clinical and pharmacy pay-
ment records of HIV-infected patients who were newly
enrolled in the Limbe ART programme between Febru-
ary 2002 and December 2005. We stratified the overall
sample into two cohorts: patients who initiated ART
before 1 October 2004; and patients who initiated ART
on or after 1 October 2004. For the sample overall and
for each cohort, we computed medians and interquartile
ranges or ranges for continuous variables and frequen-
cies for categorical variables. Enrolments per month
were compared before and after the ART price reduc-
tion using the Wilcoxon rank sum test.
We estimated unadjusted and adjusted odds ratios
(ORs) using logistic regression for the association of
patient characteristics with: 1) non-retention in care
(dropout or death); and 2) abandoning care (dropout)
immediately after initiation of ART. Separate logistic
models were fit for each characteristic of interest, and
then all characteristics were entered simultaneously in a
multiple logistic regression model, in which ORs were
adjusted for all of the other variables in the model.
Wald chi-square tests were used to test for significant
associations between patient characteristics and dropout,
and 95% confidence intervals (CIs) were computed
using the Wald method. SAS PROC LOGISTIC was
used for all logistic regression analyses.
To examine the association of factors of interest with
time to dropout or death, we fit Cox proportional
hazards models, and estimated unadjusted and adjusted
hazard ratios (HRs) and 95% CIs. Ties among time to
dropout or death were handled using the exact method.
SAS PROC PHREG was used to fit proportional hazards
models. Using SAS PROC LIFETEST, we computed
Kaplan-Meier (product-limit) curves to estimate the sur-
vivor function for remaining alive and in care.
For 25% of the patients, at least one of the covariates
of interest was missing. To avoid potential bias that may
have resulted due to the exclusion of missing data, we
used multiple imputation to estimate missing values.
Ten imputation datasets were created using a Markov
Chain Monte Carlo method with 400 burn-in iterations
before the first imputation [14]. The logistic regression
and survival analysis models were repeated using the
imputed data, and parameter estimates for the 10
imputed datasets were combined using Rubin’s methods
[15]. All analyses were completed using SAS 9.1.2,
(2004, SAS Institute Incorporated, Cary, NC, USA).
Ethical and administrative approvals for this study
were respectively obtained from the Cameroon National
Ethics Committee and the Division of Operational
Research of the Cameroon Ministry of Public Health.
Following these approvals, the project was determined
to be non-research by the National Center for HIV,
Viral Hepatitis, STD, and TB Prevention, Centers for
Disease Control and Prevention, Atlanta, Georgia, USA.
The study consisted of a retrospective analysis of clinical
and pharmacy payment records of HIV-infected patients
and therefore did not involve any consent procedure.
Results
Patients’ baseline characteristics upon enrolment in ART
Between February 2002 and December 2005, 2920
patients (62% females) initiated ART in the Limbe ART
programme (median follow-up time 6.2 months) (Table
1), contributing a total of 2463 person-years of follow
up: 1926 person-years for patients enrolled before the
ART price reduction on 1 October 2004 and 537 per-
son-years for patients enrolled after the ART price
reduction. Records of some variables of interest, includ-
ing patients’ age (4%), occupation (6%), marital status
(5%), residence distance from ART clinic (4%), means to
pay for antiretroviral drugs (20%) and entry CD4 cell
count (7%), were missing (Tables 1, 2, 3 and 4).
The median age of patients was 35 years (range 0.5-73
years). Most patients (74%) were employed (self or
casual employment, salaried workers and farmers); the
remaining patients (26%) were either unemployed or
dependent on others for support. The vast majority of
patients (96%) paid for ART through family and/or self
support; 87 (4%) received ART free of charge either
through the Global Fund programme for indigents or
from their employers.
The monthly rate of enrolment in the Limbe ART pro-
gramme generally increased over time (Figure 1) and this
increase was more marked for women than for men (data
n o ts h o w n ) .T h er a t eo fe n r o l m e n tw a sh i g h e ra f t e rt h e
ART drug price reduction on 1 October 2004: 95.5 per-
sons/month after the price reduction compared with 46.5
persons/month prior to the reduction (p < 0.001).
Clinical outcomes
As of 31 December 2005, 1597 (55%) patients remained
in care, 1149 (39%) were lost to follow up, 164 (6%)
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transferred care to another treatment centre (Table 2).
Adherence to clinical appointments was generally poor:
77% of patients were non-adherent (i.e., attended < 80%
of scheduled clinic visits); adherence for only 10% was
characterized as good (attended ≥95% of scheduled vis-
its). Notably, 22% of patients dropped out of care after
enrolling and receiving their first monthly dispensation
of ART.
Most patients initiating treatment had advanced dis-
ease, either WHO stage 3 and 4 (75%) or CDC stage B3
and C3 (86%). Although 93% of patients had a CD4 cell
c o u n tm e a s u r e da te n r o l m e n t ,o n l y6 %h a da n yf o l l o w -
up counts measured. The median baseline enrolment
CD4 cell count was 107 cells/mm
3 (IQR 36-181 cells/
mm
3, n = 2715). Median CD4 cell counts at six-monthly
visits after baseline were > 200 cells/mm
3 for most
patients for whom data were available (Figure 2).
First-and second-line ART regimens were prescribed
following national guidelines and included nucleoside
and non-nucleoside reverse transcriptase inhibitor-based
and protease inhibitor-based ART. Most patients
received first-line treatment regimens, which in 95% of
cases was a generic fixed-dosed combination of stavu-
dine, lamivudine and nevirapine (Triomune
®, Cipla,
Mumbai, India). Less than 0.5% of patients received any
second-line regimen.
Effect of drug price reduction on enrolment, retention in
care and survival
Patients enrolled before or after the ART drug price
reduction did not differ with regard to median age, sex,
Table 1 Demographic characteristics of patients initiating treatment in the Limbe ART programme, 2002 to 2005
All patients
[n(%), N = 2920]
Patients enrolled before 1 Oct 2004
[n(%), N = 1487]
Patients enrolled after 1 Oct 2004
[n(%), N = 1433]
Age category*
< 30** 723 (25.8) 357 (26.0) 366 (25.6)
30+ 2081 (74.2) 1017 (74.0) 1064 (74.4)
Median age, years (range) 35 (0.5-73) 35 (1-73) 35 (0.5-73)
Female 33 (0.7-73) 34 (1-71) 33 (0.7-72)
Male 38 (0.5-73) 38 (1-73) 37 (0.5-73)
Sex*
Female 1815 (62.3) 886 (59.6) 929 (64.8)
Male 1104 (37.7) 600 (40.4) 504 (35.2)
Median follow-up time, months (range) 6.2 (0.03-46.3) 15.8 (0.03-46.3) 3.4 (0.03-14.5)
Person-years follow up 2462.5 1925.6 536.9
Patients receiving treatment
ART naïve 2864 (98.1) 1458 (98.0) 1406 (98.1)
Patients previously on ART who were
transferred from other centres
56 (1.9) 29 (2.0) 27 (1.9)
Occupation*
Gainfully employed 2044 (74.3) 969 (73.2) 1075 (75.3)
Unemployed/dependent 706 (25.7) 354 (26.8) 352 (24.7)
Marital status*
Married 1166 (42.0) 577 (42.9) 589 (41.1)
Single 1207 (43.5) 570 (42.4) 637 (44.5)
Previous marriage 404 (14.5) 197 (14.7) 207 (14.5)
Residence by distance to ART clinic*
Residents in Limbe town 621 (22.1) 311 (22.7) 310 (21.7)
Residents < 40 km from Limbe 801 (28.6) 395 (28.8) 406 (28.4)
Residents 40-150 km from Limbe 788 (28.1) 384 (28.0) 404 (28.2)
Residents > 150 km from Limbe 454 (16.2) 217 (15.8) 237 (16.5)
Residents from Douala, 74 km away*** 139 (5.0) 64 (4.7) 75 (5.2)
Means of payment for antiretroviral drugs*
Entirely paid by programme or employer 87 (3.7) 48 (4.1) 39 (3.4)
Paid by self, family or partly by other 2241 (96.3) 1134 (95.9) 1107 (96.6)
*Sample size smaller due to missing values.
** 26 clients were < 5 years old; 20 clients were 6-10 years old; 47 clients were 11-19 years old.
*** Patients residing in Douala with regular transport on paved roads and may have had other ART opportunities Abbreviations: ART (antiretroviral therapy).
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means to pay for drugs (Table 1). Likewise, patients
enrolled before or after the ART drug price reduction did
not differ with regard to dropping out of care after initi-
ating ART, tuberculosis co-infection at the beginning or
during the course of therapy, baseline CD4 cell count
and treatment regimen received (Table 2). Adhering to
ART clinic visits was good for few patients enrolled both
before (2.9%) and after (17.6%) the price reduction.
The probabilities of remaining alive and in care were
0.66 (95% CI 0.64-0.68) at six months, 0.58 (95% CI
0.56-0.60) at one year, 0.47 (95% CI 0.45-0.49) at two
years and 0.35 (95% CI 0.32-0.38) at three years (Figure
3a). These probabilities were not significantly different
when comparing patients enrolled before with patients
enrolled after the drug price reduction over the first 15
months of comparable follow up (HR 1.1; 95% CI 0.9-
1.2) (Figure 3b).
In multivariable analysis using multiple imputations
to compensate for missing values, compared with
residents of Limbe, those living more than 150 km
from Limbe (HR 1.41 [1.18-1.69], p < 0.001) or those
who were residents of Douala (HR 1.51 [1.16-1.98], p <
0.001) were more likely to be lost to follow up or die
(Table 3). Patients who paid for care themselves or for
whom care was paid by their family or others were
more likely to be lost to follow up or die compared
with patients whose care was paid entirely by an
employer or an ART programme, such as the Global
Fund (HR 3.05; 95% CI 1.99-4.67). Men were more
likely to drop out of care or die than women (HR 1.33;
95% CI 1.18-1.50). Other factors associated with drop-
ping out of care or dying in multivariable analysis
included age less than 30 years (HR 1.25; 95% CI 1.10-
1.45) and entry CD4 cell count of less than 100 cells/
mm
3 (HR 1.41; 95% CI 1.27-1.59).
Patients who were lost to follow up after the initial
visit were more likely to be female (OR 1.22; 95% CI
1.00-1.50), to have been enrolled on or after the antire-
troviral drug price reduction on 1 October 2004 (OR
Table 2 Clinical status of patients enrolled in the Limbe ART programme, 2002 to 2005
All patients
[n(%), N =
2920]
Patients enrolled before 1 Oct
2004
[n(%), N = 1487]
Patients enrolled after 1 Oct
2004
[n(%), N = 1433]
Final clinical status (as of 31 December 2005)
In care 1597 (54.7) 663 (44.6) 934 (65.2)
Lost to follow up 1149 (39.3) 715 (48.1) 434 (30.3)
Dead 164 (5.6) 104 (7.0) 60(4.2)
Transferred 10 (0.3) 5 (0.3) 5 (0.3)
Adhering to ART clinic visits
< 80% (non-adherence) 2260 (77.4) 1286 (86.5) 974 (68.0)
80-94% (poor adherence) 365 (12.5) 158 (10.6) 207 (14.4)
> 94% (good adherence) 295 (10.1) 43 (2.9) 252 (17.6)
Dropped out of care immediately after ART initiation
Yes 631 (21.6) 295 (19.8) 336 (23.5)
No 2289 (78.4) 1192 (80.2) 1097 (76.5)
Tuberculosis co-infection at the beginning or during the
course of ART
Yes 35 (1.2) 20 (1.3) 15 (1.01)
No 2885 (98.8) 1467 (98.6) 1418 (98.9)
Median entry CD4 count, cells/mm
3 (range) 107 (0-1696) 101 (0-1696) 111 (0-958)
Entry CD4 count, (cells/mm
3)*
0-99 1287 (47.4) 659 (49.1) 628 (45.7)
> 100 1428 (52.6) 682 (50.9) 746 (54.3)
Treatment regimen on enrolment*
Stavudine/lamivudine/nevirapine 2752 (94.7) 1390 (94.3) 1362 (95.0)
Stavudine/lamivudine/efavirenz 40 (1.4) 32 (2.2) 8 (0.6)
Zidovudine/lamivudine/nevirapine 25 (0.9) 4 (0.3) 21 (1.5)
Zidovudine/lamivudine/efavirenz 82 (2.8) 40 (2.7) 42 (2.9)
Stavudine/lamivudine/indinavir 5 (0.2) 5 (0.3) 0
Zidovudine/lamivudine/indinavir 3 (0.1) 3 (0.2) 0
*Sample size smaller due to missing values.
Abbreviations: ART (antiretroviral therapy).
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employed (OR 1.27; 95% CI 1.00-1.61) (Table 4).
Discussion
A major reduction in the price of antiretrovirals in
Cameroon was associated with an increased number of
HIV-infected patients initiating ART, but did not appear
to be associated with retention in care in this setting
where most patients had to pay for their own treatment.
Retention in the Limbe ART programme decreased sub-
stantially over time: less than 50% of patients remained
in care at two years and only one-third at three years.
The proportions of patients remaining in care did not
differ according to when treatment was started (i.e.,
before or after 1 October 2004).
Though we cannot prove that the reduction in price of
ART was the only variable associated with the outcome,
the socio-economic conditions of the country did not
change appreciably during the period of the study. Paying
for ART in our study constituted a major increase in the
risk of dropout or death, and our findings are consistent
with other studies, which have demonstrated that provid-
ing ART in resource-constrained settings where people
have to pay for their own treatment was associated with
high dropout rates among persons with advanced base-
line disease [16,17]. Other studies have found self-paid
programmes were also associated with failure to achieve
viral suppression [18]; however, we were unable to exam-
ine this outcome because viral load testing was not avail-
able in Southwest Cameroon at that time.
Table 3 Factors associated with time to dropout or death among patients enrolled in the Limbe ART programme, Feb
2002-Dec 2005
Complete Cases Multiple Imputation
Characteristic n/N % Crude HR Adjusted HR Missing N(%) Crude HR Adjusted HR
(95% CI) (95% CI) (95% CI) (95% CI)
Age group
30+ 880/2081 42.3 1.00 1.00 116 1.00 1.00
< 30 350/723 48.4 1.19 (1.03, 1.37) 1.20 (1.03, 1.43) (3.97) 1.22 (1.08, 1.34) 1.25 (1.10, 1.45)
Sex*
Female 760/1815 41.9 1.00 1.00 1 1.00 1.00
Male 552/1104 50.0 1.20 (1.06, 1.36) 1.31 (1.14, 1.50) (0.03) 1.20 (1.07, 1.34) 1.33 (1.18, 1.50)
Occupation* 888/2044 43.4 1.00 1.00 170 1.00 1.00
With some kind of income
Unemployed 316/706 44.8 1.04 (0.90, 1.20) 1.06 (0.91, 1.23) (5.82) 1.01 (0.89, 1.15) 1.03 (0.90, 1.19)
Marital status*
Married/living as 501/1166 43.0 1.00 1.00 143 1.00 1.00
Never 558/1207 46.2 1.09 (0.96, 1.25) 1.10 (0.95, 1.27) (4.90) 1.14 (1.01, 1.28) 1.11 (0.98, 1.27)
Previous marriage 158/404 39.1 0.85 (0.70, 1.04) 0.94 (0.76, 1.16) 0.91 (0.76, 1.09) 1.01 (0.84, 1.21)
Residence by distance to ART clinic*
Residents in Limbe 239/621 38.5 1.00 1.00 117 1.00 1.00
Residents < 40 km from Limbe 339/801 42.3 1.13 (0.94, 1.37) 1.08 (0.89, 1.31) (4.01) 1.13 (0.96, 1.33) 1.05 (0.89, 1.23)
Residents 40-150 km from Limbe 349/788 44.3 1.15 (0.95, 1.39) 1.13 (0.93, 1.36) 1.18 (1.00, 1.39) 1.12 (0.95, 1.32)
Residents > 150 km from Limbe 236/454 52.0 1.63 (1.33, 2.00) 1.57 (1.28, 1.93) 1.52 (1.27, 2.51) 1.41 (1.18, 1.69)
Residents from Douala, 74 km away*** 72/139 51.8 1.79 (1.33, 2.40) 1.71 (1.27, 2.30) 1.66 (1.28, 2.15) 1.51 (1.16, 1.98)
Means of payment for antiretroviral drugs*
Entirely paid by programme or employer 15/87 17.2 1.00 1.00 592 1.00 1.00
Paid by self, family or partly by other 1036/2241 46.2 3.12 (1.67, 5.82) 3.34 (1.79, 6.25) (20.27) 2.95 (1.80, 4.85) 3.05 (1.99, 4.67)
Cohort
Enrolled after 1 Oct 2004 494/1433 34.5 1.00 1.00 0 N/A 1.00
Enrolled before 1 Oct 2004 819/1487 55.1 1.04 (0.91, 1.19) 1.06 (0.92, 1.21) (0.0) 1.08 (0.96, 1.22)
Entry CD4 count (cells/mm
3)*
> 100 543/1428 38.0 1.00 1.00 205 1.00 1.00
0-99 644/1287 50.0 1.43 (1.27, 1.61) 1.41 (1.25, 1.61) (7.02) 1.43 (1.28, 1.61) 1.41 (1.27, 1.59)
(complete case N = 2188; multiple imputation N = 2920).
* Sample size smaller due to missing values.
** Difficult access took into account the distance from ART centre as well as the presence of unpaved or poorly maintained road.
*** Patients residing in Douala with regular transport on paved roads and may have had other ART opportunities.
Abbreviations: ART (antiretroviral therapy).
Mosoko et al. Journal of the International AIDS Society 2011, 14:32
http://www.jiasociety.org/content/14/1/32
Page 6 of 10Affordability of antiretroviral treatment is not the only
factor that can influence retention or adherence to treat-
ment. For example, laboratory monitoring required for
patients on ART at that time cost US$30 in Cameroon
and was not readily affordable. The majority of patients
had their CD4 cell counts measured as a requirement
for entry into the treatment programme, but very few
paid for follow-up CD4 cell count testing. For the few
patients who paid for follow-up CD4 cell counts, the
increases we observed during follow up were consistent
with improved clinical outcome. Most patients pre-
sented for care with late-stage disease, possibly due to
the expense of treatment and insufficient access to
voluntary counselling and testing services. The late
entry to care we observed in the present study is consis-
tent with the findings of another Cameroonian report
that found patients usually first learn their HIV status
late in the course of infection when they have already
developed clinical signs and symptoms of AIDS [19].
Poor adherence is associated with an increased risk of
mortality [20]. Good adherence, retention in care and survi-
val have been achieved through such interventions as
home-based AIDS care [21-23] and participant-identified
support partners [24]. Adherence in the present study, mea-
sured as attendance to scheduled clinic visits, was generally
poor, with only 10% of patients attending 95% or more of
their visits. More than 20% of patients were lost to follow
up after their initial ART visit, which was due, in part, to
early deaths. The magnitude of this effect (i.e., early death
after ART initiation) was difficult to quantify since for some
patients, the date of death was unknown, and some patients
who were classified as lost to follow up may have died.
Table 4 Factors associated with dropping out of care immediately after initiating ART in the Limbe ART programme,
Feb 2002-Dec 2005
Complete Cases Multiple Imputation
Characteristic n/N % Crude HR Adjusted HR Missing N(%) Crude HR Adjusted HR
(95% CI) (95% CI) (95% CI) (95% CI)
Age group
30+ 441/2081 21.2 1.00 1.00 116 1.00 1.00
< 30 159/723 22.0 1.06 (0.83, 1.33) 1.07 (0.82, 1.40) (3.97) 1.03 (0.84, 1.27) 1.09 (0.86, 1.37)
Sex*
Male 215/1104 19.5 1.00 1.00 1 1.00 1.00
Female 416/1815 22.9 1.20 (0.77, 1.49) 1.24 (0.98, 1.57) (0.03) 1.23 (1.02, 1.49) 1.22 (1.00, 1.50)
Occupation*
Unemployed 137/706 19.4 1.00 1.00 170 1.00 1.00
With some kind of income 453/2044 22.2 1.12 (0.88, 1.43) 1.23 (0.95, 1.60) (5.82) 1.19 (0.96, 1. 49) 1.27 (1.00, 1.61)
Marital status*
Married/ living as 232/1166 19.9 1.00 1.00 143 1.00 1.00
Never 266/1207 22.0 1.07 (0.86, 1.35) 1.01 (0.79, 1.28) (4.90) 1.14 (0.94, 1.39) 1.03 (0.84, 1.27)
Previous marriage 97/404 24.0 1.13 (0.82, 1.54) 1.05 (0.76, 1.46) 1.28 (0.97, 1.68) 1.16 (0.87, 1.54)
Residence by distance to ART clinic*
Residents in Limbe 138/621 22.2 1.00 1.00 117 1.00 1.00
Residents < 40 km from Limbe 177/801 22.1 1.16 (0.87, 1.55) 1.16 (0.86, 1.57) (4.01) 1.01 (0.79, 1.29) 0.95 (0.74, 1.22)
Residents 40-150 km from Limbe 156/788 19.8 0.84 (0.62, 1.15) 0.82 (0.60, 1.13) 0.87 (0.68, 1.13) 0.83 (0.64, 1.08)
Residents > 150 km from Limbe 97/454 21.4 1.06 (0.75, 1.50) 1.04 (0.74, 1.48) 0.95 (0.71, 1.28) 0.92 (0.69, 1.23)
Residents from Douala, 74 km away*** 31/139 22.3 0.97 (0.57, 1.64) 1.00 (0.59, 1.69) 1.01 (0.65, 1.56) 0.95 (0.61, 1.47)
Means of payment for antiretroviral drugs*
Entirely paid by programme or employer 14/87 16.1 1.00 1.00 592 1.00 1.00
Paid by self, family or partly by other 456/2241 20.4 0.86 (0.46, 1.61) 0.80 (0.42, 1.52) (20.27) 1.33 (0.74, 2.39) 1.25 (0.67, 2.32)
Cohort
Enrolled before Oct 1,2004 295/1487 19.8 1.00 1.00 0 N/A 1.00
Enrolled on or after Oct 1,2004 336/1433 23.5 1.06 (0.86, 1.30) 1.05 (0.85, 1.30) (0.0) 1.22 (1.03, 1.46)
Entry CD4 count (cells/μL)
> 100 296/1428 20.7 1.00 1.00 205 1.00 1.00
0-99 292/1287 22.7 1.09 (0.88, 1.34) 1.08 (0.87, 1.33) (7.02) 1.13 (0.94, 1.35) 1.14 (0.95, 1.36)
(Complete case N = 2188; Multiple Imputation N = 2920).
*Sample size smaller due to missing values, **Difficult access took into account the distance from ART centre as well as the presence of unpaved or poorly
maintained road, ***Patients residing in Douala with regular transport on paved roads and may have had other ART opportunities. Abbreviations: ART
(antiretroviral therapy).
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urban sub-Saharan Africa [24]. Increased distance from
the Limbe ART clinic was associated with poor retention
in care. This has also been demonstrated by others in the
United States [25]. Patients who traveled to Limbe from
Douala, which had at least two ART programmes at that
time, were at greater risk of becoming lost to follow up.
This might have resulted from differences in the antire-
troviral treatment options and the quality of care that
were available in Limbe compared with Douala. Regard-
less, expanding antiretroviral treatment programmes to
be closer to more people can overcome the obstacle of
distance from clinics that may impede attendance.
Few patients had their antiretroviral drug costs and
laboratory tests paid entirely by their employer or an
ART programme. Most of these persons were employees
of a local oil refining company located in Limbe, and
had good access to the clinic.
A reduction in antiretroviral drug price in our study
was associated with increasing numbers of patients
accessing ART, but was not associated with improved
retention in care. However, free treatment, which
included payment for laboratory monitoring, was asso-
ciated with improved retention in care. This further vali-
dates the approach of the current era of antiretroviral
treatment programmes in Africa that are largely donor
supported and provide treatment and care to persons
living with HIV disease for minimal or no charge.
Requiring persons with limited resources to pay for
such care would not have been successful or sustainable
in the long term.
A strength of our analysis is its large size; we assessed
data from a large ART programme with good record
keeping and a considerable length of follow-up time for
patients, and we had access to patients’ pharmacy and
clinical payment records. However, our analysis is sub-
ject to some limitations. Data were collected retrospec-
tively and there was a low rate of immunologic follow
up since clients had to pay for the test and most could
simply not afford it; thus the CD4 cell counts available
may not reflect the CD4 cell counts of all clients while
on ART.
The extremely high rate of loss to follow up, particu-
larly after only one visit, where the outcomes of these
patients are not known, may have contributed to under-
estimation of mortality in particular. A follow-up tracing
study to characterize patients receiving ART who were
lost to follow up may be useful to enable us to under-
stand the large proportion of those who were lost only
after one visit. There was no virologic monitoring avail-
able during that time in this part of Cameroon. To over-
come potential bias resulting from exclusion of missing
data, we employed multiple imputation to generate esti-
mated values for missing data and the abandoned care
analyses found that cohort was a predictive factor only
when imputed data was included.
Conclusions
We found that proximity to care was associated with
improved outcomes, regardless of the cost of therapy.
However, many patients sought care late in the course
of their infection, did not return for scheduled clinic vis-
its, and were lost to care. If poor retention in care is a
proxy for poor adherence to taking antiretroviral drugs
as prescribed, then our findings should raise concern
that in programmes where patients must pay for their
own care, selective pressure favouring drug resistance
might be increased.
Cameroon now has an ongoing policy to expand free
ART that should improve survival and retention in care.
ART price reduction Oct 2004 
Mean = 46.5 
Mean = 95.5 
Figure 1 Retention in an antiretroviral therapy programme
during an era of decreasing drug cost in Limbe, Cameroon.
Monthly enrolment of patients initiating antiretroviral therapy (ART)
in the Limbe ART programme, 2002-2005, Cameroon.
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Figure 2 Median (interquartile range) CD4 cell counts for
patients enrolled in the Limbe antiretroviral (ART) programme
measured at six-month intervals after staring ART, 2002-2005,
Cameroon. CD4 cell counts were paid for by the client and were
available for relatively few persons while on ART.
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Page 8 of 10Decentralizing ART clinics and linking them with
increased voluntary counselling and testing services may
reduce late presentation to care and thereby further
improve survival and retention in care in Cameroon.
The data from this report will serve as an historical
comparison to the current approach that provides free
ART.
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